Bevacizumab biosimilar is under clinical development by Synermore Biologics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bevacizumab biosimilar’s likelihood of approval (LoA) and phase transition for Peritoneal Cancer took place on 17 Nov 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bevacizumab biosimilar Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bevacizumab biosimilar overview

Bevacizumab biosimilar (SYN-050) is under development for the treatment of metastatic breast cancer, metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic cervical cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The drug candidate is administered through intravenous route. It acts by targeting vascular endothelial growth factor A (VEGFA). It was also under development for the treatment of metastatic renal cell carcinoma.

Synermore Biologics overview

Synermore Biologics (Synermore) is a biotechnology company that researches and develops biosimilar monoclonal antibodies. It develops its products in the therapeutic areas of oncology, immune disorders and infectious diseases. Its pipeline products include SYN004, SYN008, SYN125, SYN050, SYN060, SYN112, SYN109 and others. Synermore has developed technologies and platforms necessary for the development and production of therapeutic monoclonal antibodies including preparation and screening of hybridomas, antibody engineering and humanization, cell line construction and screening, CHO cell based culture platforms for high-density antibody expression, fermentation and purification, advanced analytical technologies for antibody characterization, and antibody drug formulation. The company also operates though its office located in Suzhou, China. Synermore is headquartered in Taipei City, Taiwan.

Quick View Bevacizumab biosimilar LOA Data

Report Segments
  • Biosimilar
Drug Name
  • Bevacizumab biosimilar
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.